Humana (NYSE:HUM) Price Target Raised to $349.00 at Deutsche Bank Aktiengesellschaft

Humana (NYSE:HUM) had its target price hoisted by Deutsche Bank Aktiengesellschaft from $341.00 to $349.00 in a report released on Friday morning, Benzinga reports. The firm currently has a hold rating on the insurance provider’s stock.

Other equities research analysts have also issued research reports about the company. Royal Bank of Canada lowered their price objective on Humana from $415.00 to $353.00 and set an outperform rating on the stock in a research report on Thursday, April 25th. Bank of America upped their price objective on Humana from $342.00 to $376.00 and gave the stock a neutral rating in a research report on Monday, May 20th. Baird R W upgraded Humana to a hold rating in a research report on Thursday, May 30th. Wells Fargo & Company decreased their target price on Humana from $413.00 to $350.00 and set an overweight rating on the stock in a research report on Monday, April 8th. Finally, Cantor Fitzgerald reiterated a neutral rating and set a $360.00 target price on shares of Humana in a research report on Tuesday, July 23rd. Fourteen equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of Hold and a consensus price target of $403.55.

Humana Stock Up 0.1 %

Shares of HUM traded up $0.35 during mid-day trading on Friday, hitting $356.64. 288,216 shares of the company traded hands, compared to its average volume of 1,735,787. The business has a 50 day moving average of $368.04 and a 200 day moving average of $347.41. The company has a market capitalization of $42.94 billion, a PE ratio of 22.10, a price-to-earnings-growth ratio of 2.09 and a beta of 0.51. Humana has a 1-year low of $298.61 and a 1-year high of $530.54. The company has a quick ratio of 1.67, a current ratio of 1.66 and a debt-to-equity ratio of 0.70.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping the consensus estimate of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The business had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter in the prior year, the firm posted $8.94 EPS. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. Equities research analysts anticipate that Humana will post 16.14 EPS for the current year.

Institutional Trading of Humana

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rakuten Securities Inc. acquired a new stake in shares of Humana during the 4th quarter worth about $25,000. Cetera Trust Company N.A purchased a new position in Humana during the 4th quarter valued at about $28,000. Private Wealth Management Group LLC purchased a new position in Humana during the 4th quarter valued at about $32,000. CarsonAllaria Wealth Management Ltd. boosted its holdings in Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after acquiring an additional 39 shares during the period. Finally, Hantz Financial Services Inc. purchased a new position in Humana during the 2nd quarter valued at about $35,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.